Uniting science, technology and talent to get ahead of disease together
GSK is changing. We expect to demerge our world leading consumer healthcare business, Haleon, in July 2022. After the demerger, we will be a fully focused biopharma company with a new purpose; to unite science, technology and talent to get ahead of disease together.
We aim to impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. GSK will be a company where outstanding people can thrive.
We will prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccine and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology including respiratory diseases.
We’re focused on making GSK a place where everyone can be ambitious for patients, accountable for their impact and always do the right thing. Our Code outlines the commitments we ask everyone at GSK to put their name to with pride.
We have updated our branding to reflect our new purpose and growth ambitions. It combines science, technology and talent, while retaining key elements of our heritage. We will roll out our new branding across our product packaging, physical locations and digital presence in the coming months.